دورية أكاديمية
أعرض في EDS

Adenosine A 2A and dopamine D 2 receptor interaction controls fatigue resistance.

التفاصيل البيبلوغرافية
العنوان: Adenosine A 2A and dopamine D 2 receptor interaction controls fatigue resistance.
المؤلفون: Alves ACB; Biology of Exercise Lab, Department of Health Sciences, UFSC-Federal University of Santa Catarina, Araranguá, Brazil., Santos NS; Biology of Exercise Lab, Department of Health Sciences, UFSC-Federal University of Santa Catarina, Araranguá, Brazil., Santos APT; Biology of Exercise Lab, Department of Health Sciences, UFSC-Federal University of Santa Catarina, Araranguá, Brazil., da Panatta G; Biology of Exercise Lab, Department of Health Sciences, UFSC-Federal University of Santa Catarina, Araranguá, Brazil., Speck AE; Biology of Exercise Lab, Department of Health Sciences, UFSC-Federal University of Santa Catarina, Araranguá, Brazil., Cunha RA; CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.; FMUC-Faculty of Medicine, University of Coimbra, Coimbra, Portugal., Aguiar AS Jr; Biology of Exercise Lab, Department of Health Sciences, UFSC-Federal University of Santa Catarina, Araranguá, Brazil.
المصدر: Frontiers in pharmacology [Front Pharmacol] 2024 May 27; Vol. 15, pp. 1390187. Date of Electronic Publication: 2024 May 27 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Media]
مستخلص: Introduction: Caffeine and the selective A 2A receptor antagonist SCH58261 both have ergogenic properties, effectively reducing fatigue and enhancing exercise capacity. This study investigates in male Swiss mice the interaction between adenosine A 2A receptors and dopamine D 2 receptors controlling central fatigue, with a focus on the striatum where these receptors are most abundant. Methods: We employed DPCPX and SCH58261 to antagonize A 1 and A 2A receptors, caffeine as a non-competitive antagonist for both receptors, and haloperidol as a D 2 receptor antagonist; all compounds were tested upon systemic application and caffeine and SCH58261 were also directly applied in the striatum. Behavioral assessments using the open field, grip strength, and treadmill tests allowed estimating the effect of treatments on fatigue. Results and discussion: The results suggested a complex interplay between the dopamine and adenosine systems. While systemic DPCPX had little effect on motor performance or fatigue, the application of either caffeine or SCH58261 was ergogenic, and these effects were attenuated by haloperidol. The intra-striatal administration of caffeine or SCH58261 was also ergogenic, but these effects were unaffected by haloperidol. These findings confirm a role of striatal A 2A receptors in the control of central fatigue but suggest that the D 2 receptor-mediated control of the ergogenic effects of caffeine and of A 2A receptor antagonists might occur outside the striatum. This prompts the need of additional efforts to unveil the role of different brain regions in the control of fatigue.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
(Copyright © 2024 Alves, Santos, Santos, Panatta, Speck, Cunha and Aguiar.)
References: Neuroscience. 2010 Sep 29;170(1):268-80. (PMID: 20600675)
Biol Psychol. 2022 Nov;175:108442. (PMID: 36243197)
Brain Commun. 2021 Jun 08;3(3):fcab116. (PMID: 34423297)
Neuropharmacology. 2012 Apr;62(5-6):2068-77. (PMID: 22261384)
Neuroscience. 2000;97(1):195-204. (PMID: 10771351)
Behav Brain Res. 2009 Jul 19;201(1):216-22. (PMID: 19428636)
J Caffeine Adenosine Res. 2019 Sep 1;9(3):89-97. (PMID: 31559390)
Eur J Pharmacol. 2004 Sep 19;499(1-2):147-54. (PMID: 15363961)
Neuropharmacology. 2023 Mar 15;226:109421. (PMID: 36634866)
J Pharmacol Exp Ther. 2007 Nov;323(2):708-19. (PMID: 17684118)
Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):654-9. (PMID: 17194762)
Neuropharmacology. 2016 May;104:154-60. (PMID: 26051403)
J Biol Chem. 2003 Nov 21;278(47):46741-9. (PMID: 12933819)
Purinergic Signal. 2024 Feb;20(1):29-34. (PMID: 36918462)
Pharmacol Rev. 1999 Mar;51(1):83-133. (PMID: 10049999)
Neurosci Biobehav Rev. 2016 Sep;68:370-386. (PMID: 27235078)
Front Pharmacol. 2018 Jan 10;8:985. (PMID: 29375384)
Sci Rep. 2020 Aug 7;10(1):13414. (PMID: 32770138)
Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R399-404. (PMID: 12399249)
Purinergic Signal. 2023 Dec;19(4):673-683. (PMID: 36697868)
Br J Pharmacol. 2000 Apr;129(7):1465-73. (PMID: 10742303)
Sci Rep. 2017 Feb 08;7:42323. (PMID: 28176863)
Curr Pharm Des. 2008;14(15):1468-74. (PMID: 18537670)
Psychopharmacology (Berl). 1999 Nov;147(1):90-5. (PMID: 10591873)
Brain Res. 2019 Jun 15;1713:102-108. (PMID: 30171838)
Transl Psychiatry. 2012 Oct 23;2:e176. (PMID: 23092980)
Neuroscience. 1997 Oct;80(4):1171-85. (PMID: 9284069)
J Neurosci. 2008 Mar 19;28(12):2970-5. (PMID: 18354001)
Purinergic Signal. 2021 Sep;17(3):393-397. (PMID: 34216353)
Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7238-41. (PMID: 1678519)
Naunyn Schmiedebergs Arch Pharmacol. 2018 Dec;391(12):1361-1371. (PMID: 30094458)
Gen Physiol Biophys. 2017 Oct;36(4):431-441. (PMID: 28857746)
Sci Rep. 2018 Jul 16;8(1):10742. (PMID: 30013130)
Ann Neurol. 2008 Mar;63(3):338-46. (PMID: 18300283)
Neurotox Res. 2016 Jan;29(1):118-25. (PMID: 26464310)
Eur J Neurosci. 2018 May;47(9):1127-1134. (PMID: 29570875)
Neurology. 2003 Dec 9;61(11 Suppl 6):S19-23. (PMID: 14663004)
Front Pharmacol. 2018 Jan 04;8:899. (PMID: 29354052)
Dis Model Mech. 2015 Jan;8(1):57-63. (PMID: 25398851)
Behav Brain Res. 2013 Jun 15;247:217-26. (PMID: 23557694)
Eur Neuropsychopharmacol. 2013 Apr;23(4):317-28. (PMID: 22561003)
Exp Physiol. 2021 Dec;106(12):2294-2298. (PMID: 32176398)
Front Pharmacol. 2018 Apr 24;9:393. (PMID: 29740319)
Mov Disord. 2003 Oct;18(10):1108-14. (PMID: 14534913)
J Nucl Med. 2012 Nov;53(11):1723-9. (PMID: 22966134)
Trends Pharmacol Sci. 2018 Dec;39(12):1008-1020. (PMID: 30384981)
Biochem Pharmacol. 2019 Aug;166:313-321. (PMID: 31199895)
Exp Mol Med. 2017 Oct 6;49(10):e384. (PMID: 28983090)
Bull Exp Biol Med. 2010 Aug;149(2):226-32. (PMID: 21113497)
Physiol Rev. 2001 Oct;81(4):1725-89. (PMID: 11581501)
J Biol Chem. 2002 May 17;277(20):18091-7. (PMID: 11872740)
Psychopharmacology (Berl). 2023 Oct;240(10):2173-2185. (PMID: 37615683)
Int J Mol Sci. 2021 Feb 12;22(4):. (PMID: 33673282)
Mol Neurobiol. 2021 Apr;58(4):1782-1791. (PMID: 33394335)
Sports Med. 2006;36(10):881-909. (PMID: 17004850)
J Appl Physiol (1985). 2010 Sep;109(3):886-94. (PMID: 20595537)
Psychopharmacology (Berl). 2000 Feb;148(2):153-63. (PMID: 10663430)
Mol Psychiatry. 2015 Nov;20(11):1373-85. (PMID: 25560761)
Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8606-11. (PMID: 10890919)
Biol Psychiatry. 2014 Jun 1;75(11):855-63. (PMID: 23820821)
Sports Med. 2005;35(9):757-77. (PMID: 16138786)
Psychopharmacology (Berl). 1991;103(4):541-4. (PMID: 2062988)
فهرسة مساهمة: Keywords: DPCPX; SCH58261; caffeine; central fatigue; haloperidol; striatum
تواريخ الأحداث: Date Created: 20240611 Latest Revision: 20240612
رمز التحديث: 20240612
مُعرف محوري في PubMed: PMC11163034
DOI: 10.3389/fphar.2024.1390187
PMID: 38860172
قاعدة البيانات: MEDLINE
الوصف
تدمد:1663-9812
DOI:10.3389/fphar.2024.1390187